Benign prostatic enlargement management
Expert-Guided Poster Tour 07

Saturday 16 March
15:30 - 17:30

Location: Green Area, Room B
Chairs: J-N.L. Cornu, Rouen (FR)
S.M. Haensel, Rotterdam (NL)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts will ask questions to individuals and groups of poster presenters.

16:00 - 16:03
Introduction
S.M. Haensel, Rotterdam (NL)

PT164
Benign prostatic hyperplasia increases the risk of colon cancer: A population-based study

By: Lai B.C.H. 1, Shih H-J. 1, Huang C-J. 2
1Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, 2Wan Fang Hospital, Dept. of Anesthesiology, Taipei, Taiwan

Aims and objectives of this presentation
PT164

PT165
Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories

By: Della Pasqua O. 1, D'Agate S. 2, Adalig B. 3, Wilson T. 4, Chavan C. 5, Manyak M. 6, Palacios-Moreno J.M. 7, Oelke M. 8, Roehrborn C. 9
1GlaxoSmithKline, Dept. of Urology, London, United Kingdom, 2University College London, Clinical Pharmacology and Therapeutics Group, London, United Kingdom, 3GlaxoSmithKline, Dept. of Urology, Istanbul, Turkey, 4PAREXEL International, Dept. of Statistics, Durham, United States of America, 5GlaxoSmithKline, Dept. of Urology, Mumbai, India, 6GlaxoSmithKline, Dept. of Urology, Washington, United States of America, 7GlaxoSmithKline, Dept. of Urology, Madrid, Spain, 8St. Antonius Hospital, Dept. of Urology, Gronau, Germany, 9University of Texas Southwestern Medical Center, Dept. of Urology, Texas, United States of America

Aims and objectives of this presentation
PT165
**PT166**

**Management of urinary retention in patients with benign prostatic obstruction: A systematic review and meta-analysis**


¹Athens Medical Center, Dept. of Minimally Invasive Urology, Athens, Greece, ²University of Patras, Dept. of Urology, Patras, Greece, ³University of Aberdeen, Academic Urology Unit, Aberdeen, Scotland, United Kingdom, ⁴School of Health Sciences, University of Thessaly, Dept. of Urology, Faculty of Medicine, Larissa, Greece, ⁵Charles-Nicolle University Hospital, Dept. of Urology, Rouen Cedex, France, ⁶Bristol Medical School, University of Bristol and Bristol Urological Institute, Translational Health Sciences, Bristol, United Kingdom, ⁷University of Florence AOUC- Careggi Hospital, Minimally Invasive and Robotic Surgery, and Kidney Transplantation, Florence, Italy, ⁸Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, ⁹Spital Thurgau AG, Urology Clinic, Frauenfeld, Switzerland, ¹⁰Kaiser-Franz-Josef-Spital, Dept. of Urology, Vienna, Austria, ¹¹University Basel, Alta Uro AG, Basel, Switzerland, ¹²Taunton and Somerset Hospital, Dept. of Urology, Taunton, United Kingdom, ¹³University of Helsinki and Helsinki University Hospital, Dept. of Urology and Public Health, Helsinki, Finland, ¹⁴Health Sciences Centre, McMaster University, Division of Gastroenterology and Cochrane UGPD Group, Dept. of Medicine, Hamilton, Canada, ¹⁵University General Hospital of Heraklion, University of Crete Medical School, Dept. of Urology, Heraklion, Crete, Greece

**Aims and objectives of this presentation**

PT166

**PT167**

**Detrusor wall thickness does not predict a successful trial without catheter after acute urinary retention in patients on medical treatment for benign prostatic hyperplasia**

By: De Nunzio C.¹, Tema G.¹, Cindolo L.², Bada M.², Lombardo R.¹, Cicione A.¹, Nacchia A.¹, Cancrini F.¹, Schips L.², Gacci M.³, Milanese M.³, Cito G.³, Serri S.³, Tubaro A.¹

¹Sapienza University of Rome, Sant’Andrea Hospital, Dept. of Urology, Rome, Italy, ²S.Pio da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, ³University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy

**Aims and objectives of this presentation**

PT167

**PT168**

**The outcomes of male patients with acute urinary retention with concomitant post-obstructive diuresis**

By: Fishelevitz A., Leibovitch I., Vainrib M.

Meir Medical Center, Dept. of Urology, Kfar Saba, Israel

**Aims and objectives of this presentation**

PT168
<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT169</td>
<td>Is it clinically useful to screen all patients with LUTS for erectile</td>
<td>Capogrosso P., Ventimiglia E., Boeri L., Pozzi E., Schifano N., Chierigo F., Belladelli F., Cazzaniga W., Abbate C., Dehò F., Mirone V., Gaboardi F., Montorsi F., Salonia A.</td>
<td>1IRCCS Ospedale San Raffaele, Unit of Urology, URI, Milan, Italy, 2Università Vita-Salute San Raffaele, Unit of Urology, URI, Milan, Italy, 3University of Naples “Federico II”, Department of Neurosciences, Sciences of Reproduction and Odontology, Urology Unit, Naples, Italy, 4IRCCS Ospedale San Raffaele Turro, Unit of Urology, URI, Milan, Italy</td>
<td>PT169</td>
</tr>
<tr>
<td>PT170</td>
<td>Validation of a clinical decision-making Markov model applied to</td>
<td>Ferrari R., Schiavina R., Borghesi M., Bianchi L., Chessa F., Brunocilla E., Crivellaro S.</td>
<td>1University of Bologna, Dept. of Urology, Bologna, Italy, 2University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America</td>
<td>PT170</td>
</tr>
<tr>
<td>PT171</td>
<td>A high preoperative PSA level is not accurate to predict incidental</td>
<td>Misrai V., Peyronnet B., Pradere B., Bordier B., Guillotreau J., Gryn A., Zorn K.C.</td>
<td>1Clinique Pasteur, Dept. of Urology, Toulouse, France, 2Rennes University, Dept. of Urology, Rennes, France, 3University of Tours, Dept. of Urology, Tours, France, 4CHUM university, Dept. of Urology, Montréal, Canada</td>
<td>PT171</td>
</tr>
<tr>
<td>PT172</td>
<td>Postoperative PSA levels after holmium laser enucleation of the</td>
<td>Kimura S., Ohara E., Aoki H., Ishidoya S.</td>
<td>Sendai City Hospital, Dept. of Urology, Sendai, Japan</td>
<td>PT172</td>
</tr>
<tr>
<td>PT173</td>
<td>Diagnosing incidental prostate cancer (pT1a/b): Is the game worth the</td>
<td>Misrai V., Peyronnet B., Pradere B., Bordier B., Guillotreau J., Gryn A., Zorn K.C.</td>
<td>1Clinique Pasteur, Dept. of Urology, Toulouse, France, 2Rennes University, Dept. of Urology, Rennes, France, 3University of Tours, Dept. of Urology, Tours, France, 4CHUM university, Dept. of Urology, Montréal, Canada</td>
<td>PT173</td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

PT173

How should we screen out prostate cancer from benign prostate hyperplasia patients? Analysis of 764 cases treated with Holmium laser enucleation of the prostate in a tertiary institution

By: Kimura S., Ohara E., Aoki H., Shibuya R., Naganuma H., Ishidoya S.
Sendai City Hospital, Dept. of Urology, Sendai, Japan, Sendai City Hospital, Dept. of Pathology, Sendai, Japan

Aims and objectives of this presentation

PT174

Preoperative pelvic floor muscle exercise for early continence after holmium laser enucleation of the prostate: A randomized controlled study

By: Anan G., Iwamura H., Ito J., Kaiho Y., Sato M.
Tohoku Medical and Pharmaceutical University, Dept. of Urology, Sendai, Japan

Aims and objectives of this presentation

PT175

Holmium laser enucleation of the prostate (HoLEP): Evaluation of the first thousand patients

By: Placer J., Salvador C., Narváez M.A., Celma A., Planas J., Trilla E., Lorente D., Morote J.
Vall d’Hebron University Hospital, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation

PT176

Track and teach: Simplified endoscope tracking in prostate enucleation reveals differing motion patterns dependent on surgeon experience

By: Dressler F.F., Gratzke C., Miernik A., Schöb D.S.
University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany

Aims and objectives of this presentation

PT177

Partially versus totally en-bloc no-touch low-power HoLEP: Comparable safety and efficacy, improved post-operative dysuria

By: Cracco C.M., Scoffone C.M.
Scientific Programme - EAU19 Barcelona

Cottolengo Hospital, Dept. of Urology, Turin, Italy

Aims and objectives of this presentation
PT178

PT179

Holmium laser transurethral enucleation of the prostate 100 W vs 120 W: 12-month retrospective data from a single surgeon experience

By: Franco M., Sanchez Macias J., Mercader C., Pardo A., Camacho Rovira D., Calaf O., D'Anna M., Rifa Lapieza L., Alcaraz A.
1Hospital Clinic, Dept. of Urology, Barcelona, Spain, 2Laseralia, C.E.O., Barcelona, Spain, 3Hospital Germans Trias, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation
PT179

PT180

The influences of preoperative acute urinary retention to holmium laser enucleation of prostate: Multicenter analysis

1The Catholic University of Korea, Uijeongbu St.Mary's Hospital, Dept. of Urology, Gyeonggi-do, South Korea, 2Konkuk University Chungju Hospital, Dept. of Urology, Chungcheongbuk-do, South Korea, 3Chungnam National University Hospital, Dept. of Urology, School of Medicine, Daejeon, South Korea, 4Konyang University College of Medicine, Dept. of Urology, Daejeon, South Korea

Aims and objectives of this presentation
PT180

PT181

Thulium laser enucleation (ThuFLEP) versus Holmium laser enucleation of the prostate (HolEP): A two institution trial to compare intra and early postoperative outcomes

By: Bozzini G., Roche J.B., Besana U., Romero Otero J., Gastaldi C., Calori A., Buizza C.
1ASST Valle Olona, Dept. of Urology, Busto Arsizio, Italy, 2Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, 3Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain

Aims and objectives of this presentation
PT181

PT182

Initial results of a prospective randomized trial on the learning curve of three endoscopic enucleation techniques (HoLEP, ThuFLEP and MEP) for BPH

By: Taratkin M., Enikeev D., Rapoport L., Enikeev M., Glybochko P.
Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

Aims and objectives of this presentation
PT182
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT186</td>
<td>Aquablation for treating benign prostatic obstruction in small to medium-size glands: 6 months-outcomes of the first French registry</td>
<td>Misrai V., Barry Delongchamps N., Descazeaud A.</td>
<td>Clinique Pasteur, Dept. of Urology, Toulouse, France, Cochin Hospital, Dept. of Urology, Paris, France, Dupuytren Hospital, Dept. of Urology, Limoges, France</td>
<td></td>
</tr>
<tr>
<td>PT187</td>
<td>Aquablation of the prostate. Real-life data from 180 consecutive patients</td>
<td>Bach T., Giannakis I., Karimi M., Rijo E.</td>
<td>Asklepios Hospital Harburg, Dept. of Urology, Hamburg, Germany, Kantonspital Frauenfeld, Dept. of Urology, Frauenfeld, Switzerland, Hospital Quirón Barcelona, Dept. of Urology, Hamburg, Germany</td>
<td></td>
</tr>
</tbody>
</table>
PT188  Venous thromboembolism (VTE) prophylaxis following transurethral resection of the prostate (TURP): A national audit of practice in Scotland

By: Small R., Leask J., McPhee A.S., Bhatt J.R.
Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom

Aims and objectives of this presentation
PT188

PT189  Inferior tissue ablation after 120W greenlight laser vaporization does not result into inferior clinical outcome compared to conventional TURP: Update of a prospective 3D ultrasound volumetry study after 5 years

By: Kranzbühler B., Gross O., Fankhauser C., Wettstein M., Grossmann N., Keller E., Eberli D., Sulser T., Poyet C., Hermanns T.
University Hospital Zürich, Dept. of Urology, Zurich, Switzerland

Aims and objectives of this presentation
PT189

PT190  Anticoagulants continued during PVP does not impact the risk of postoperative hemorrhagic complications: A multicentric prospective study

By: Pradere B., Naspro R., Peyronnet B., Guillotreau J., Bordier B., Misrai V.
1CHRU Tours, Dept. of Urology, Tours, France, 2ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, France, 3CHU Rennes, Dept. of Urology, Rennes, France, 4Clinique Pasteur, Dept. of Urology, Toulouse, France

Aims and objectives of this presentation
PT190

PT191  Clinical comparison of holmium laser enucleation of the prostate (HoLEP) and bipolar transurethral enucleation of the prostate (BTUEP) in patients under either anticoagulation or antiplatelet therapy

1IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology; URI, Milan, Italy, 2IRCCS Fondazione Ca’ Granda - Maggiore Policlinico Hospital, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation
PT191

PT192  A prospective, randomized controlled trial (RCT) regarding antimicrobial prophylaxis in transurethral resection of the prostate (TURP): An interim analysis of the prophylaxis001-trial

By: Baten E., Arijs I., Goethuys H., Vandecandelae M., Cartuyvels R., Van
Aims and objectives of this presentation

PT192